When does rucaparib’s patent (and market exclusivity) expire?
Rucaparib’s patent expiry depends on which country and which patent family is being considered. Patent terms are set per jurisdiction and can differ by grant date and any adjustments. In practice, for cancer drugs like rucaparib, “when you can expect generic competition” is usually driven by a mix of primary patents and later-expiring secondary protections (for example, formulations, specific uses, or combination regimens), plus any regulatory exclusivity that can extend market protection after the last patent expires.
How can I find the exact expiry date for rucaparib in my country?
To get a precise expiry date, you typically need:
- the relevant jurisdiction (US, UK, EU, Canada, etc.)
- the specific rucaparib product name used locally (it can matter for which patents and exclusivity are listed)
- whether you care about “patent expiry” specifically or “exclusivity expiry” (which can extend beyond the last patent)
The most reliable approach is to check national patent registers or drug-specific regulatory exclusivity listings (for example, US Orange Book for US listings; UK/EU patent and regulator resources in Europe). Those sources list each patent number and its stated expiration date, plus any exclusivity period that applies.
Is rucaparib a single patent situation or multiple overlapping patents?
It is usually multiple overlapping patents. Even when the “headline” patent expires, other patents can keep preventing full generic entry for specific indications, formulations, or dosages until they also expire. This is common for oncology small-molecule drugs with ongoing lifecycle management.
Could generics or biosimilars enter before all patents expire?
For small-molecule drugs like rucaparib, generic entry timing depends on whether the generic company can carve out, avoid, or wait out specific protected elements. Regulatory filings may reference the originator while still facing patent litigation or design-around limits.
What lawsuits or “patent challenges” would affect timing?
The start of generic competition can shift when originator companies sue over patent infringement or when generics challenge patent validity. Those events can delay launch even if patents are close to expiration.
If I tell you the country, can you pinpoint the expiry date?
Yes. Share:
1) the country (or region) you mean, and
2) the rucaparib product/brand name you’re looking at (if applicable), and
I can map out the relevant patent(s)/exclusivity timing using the sources that apply to that jurisdiction.
Sources
No sources were provided with your question, so I can’t reliably cite specific rucaparib patent expiration dates yet.